quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:15:08·86d
ANALYSTRating
Aardvark Therapeutics Inc. logo

B. Riley Securities initiated coverage on Aardvark Therapeutics with a new price target

AARD· Aardvark Therapeutics Inc.
Health Care
Original source

Companies

  • AARD
    Aardvark Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 2UpdateStifel$6.00
  • Mar 2UpdateMorgan Stanley$7.00
  • Mar 2UpdateRBC Capital Mkts$6.00
  • Mar 2UpdateH.C. Wainwright-
  • Jan 28UpdateB. Riley Securities$32.00
  • Dec 23UpdateOppenheimer$35.00

Related

  • SEC18d
    SEC Form EFFECT filed by Aardvark Therapeutics Inc.
  • SEC20d
    SEC Form 424B5 filed by Aardvark Therapeutics Inc.
  • SEC31d
    SEC Form S-3 filed by Aardvark Therapeutics Inc.
  • SEC31d
    SEC Form 10-K filed by Aardvark Therapeutics Inc.
  • SEC31d
    Aardvark Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR31d
    Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
  • ANALYST52d
    Aardvark Therapeutics downgraded by Stifel with a new price target
  • ANALYST52d
    Aardvark Therapeutics downgraded by Morgan Stanley with a new price target
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022